[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005272
German
Original Title:
Tremelimumab und Durvalumab (hepatozelluläres Karzinom)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-27.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-27-und-a23-30_tremelimumab-und-durvalumab_nutzenbewertung-35a-sgb-v_v1-1.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Carcinoma, Hepatocellular
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Liver Neoplasms
Keywords
- Durvalumab
- Tremelimumab
- Carcinoma – Hepatocellular
- Benefit Assessment
- NCT03298451
- NCT03434379
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.